SOX2 and cancer: Furthermore, PDS-dependent Pembrolizumab responses with lower T cells killing capacities, were strongly associated with high expression of SOX2 gene in cancer cells, in agreement with a role for SOX2 in the maintenance of CSC features and the tumor-intrinsic mediated resistance to immune checkpoint blockade72–74.